2022.03.31 I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment
2022.03.29 I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021
2022.03.18 I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022
2022.03.09 I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
2022.03.03 I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer
2022.02.03 Endpoints: I-Mab expands manufacturing for multiple myeloma antibody; Granules issued ‘minor observations’ after inspection
2022.01.28 I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs
2022.01.18 I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors